Press Release

IMPACT Therapeutics, Seven and Eight Biopharma Announce Global License, Collaboration Agreements With Eikon

June 14, 2023

Palo Alto and Shanghai – June 14, 2023 – Cooley advised IMPACT Therapeutics and Seven and Eight Biopharmaceuticals on their respective license and collaboration agreements with Eikon Therapeutics, a biotechnology company. Partners Lila Hope and Yiming Liu led the Cooley team advising IMPACT. Hope, Steve Przesmicki and Bin Wang led the Cooley team advising Seven and Eight.

IMPACT is a biopharmaceutical company dedicated to the discovery and development of targeted anti-cancer innovative drugs based on synthetic lethality. IMPACT’s agreement grants Eikon an exclusive license to co-develop, register, manufacture and commercialize IMPACT’s PARP1 selective inhibitors – including IMP1734 – globally, excluding Greater China. The collaboration will allow IMPACT to accelerate the development of its PARP1 inhibitors, which exploit DNA damage response irregularities often found in tumors to selectively kill cancer cells.

Seven and Eight is a clinical-stage biotechnology company focused on the development and commercialization of novel immunotherapies for cancer. Its agreement also grants Eikon exclusive global rights to develop and commercialize TLR7/8, Seven and Eight’s novel immune modulator agonists targeting toll-like receptor 7 and 8, as well as novel toll-like receptor ligand antibody conjugation molecules.

About Cooley LLP

Clients partner with Cooley on transformative deals, complex IP and regulatory matters, and high-stakes litigation, where innovation meets the law.

Cooley has 1,400 lawyers across 18 offices in the United States, Asia and Europe, and a total workforce of more than 3,000.

This content is provided for general informational purposes only, and your access or use of the content does not create an attorney-client relationship between you or your organization and Cooley LLP, Cooley (UK) LLP, or any other affiliated practice or entity (collectively referred to as “Cooley”). By accessing this content, you agree that the information provided does not constitute legal or other professional advice. This content is not a substitute for obtaining legal advice from a qualified attorney licensed in your jurisdiction and you should not act or refrain from acting based on this content. This content may be changed without notice. It is not guaranteed to be complete, correct or up to date, and it may not reflect the most current legal developments. Prior results do not guarantee a similar outcome. Do not send any confidential information to Cooley, as we do not have any duty to keep any information you provide to us confidential. This content may be considered Attorney Advertising and is subject to our legal notices.